What is the primary purpose of this 10-Q filing?

The primary purpose of this 10-Q filing is to provide investors and the public with Amgen Inc.'s unaudited financial results and other relevant business information for the fiscal quarter ending June 29, 1994. It's a standard requirement for publicly traded companies to disclose their performance regularly.

Where can I find the detailed financial statements and analysis from this report?

The provided text is a directory listing and does not contain the detailed financial statements or management's discussion and analysis. To access this information, you would need to locate and review the full 10-Q document filed by Amgen Inc. on August 9, 1994, typically available through the SEC's EDGAR database or other financial data providers.

What key products or developments might Amgen have been focused on in mid-1994?

Based on the information provided, it's not possible to determine Amgen's specific product focus or developments in mid-1994. However, historical context indicates that Amgen was a pioneer in biotechnology, with key products like Epogen (epoetin alfa) and Neupogen (filgrastim) already established or in significant growth phases during that era. Investors would need to consult the full 10-Q's Management's Discussion and Analysis section for details on product performance, pipeline updates, and strategic initiatives.

Is this report relevant for current investment decisions in Amgen?

This 10-Q filing from 1994 is primarily of historical interest. It reflects Amgen's financial position and operational environment over 30 years ago. For current investment decisions, investors should focus on Amgen's most recent SEC filings (e.g., the latest 10-Q and 10-K) which provide up-to-date information on the company's current financial health, strategic direction, and market performance.

AMGN 10-Q Quarterly Report Q2 FY1994 — Revenue, Net Income, EPS

Summary

Amgen Inc. (AMGN) filed its quarterly report for the period ending June 29, 1994. This filing provides a snapshot of the company's financial performance and operational status during the second quarter of 1994. Investors should note that this report is from 1994, a significantly different time for the biotechnology industry and Amgen itself. Key financial details and strategic initiatives from this period would need to be contextualized against historical market conditions and the company's then-current product pipeline and regulatory environment. While specific financial figures and narrative discussions are not detailed in the provided excerpt, the filing itself indicates Amgen was actively reporting its financial standing to investors. Investors interested in this period should seek the full 10-Q document to understand revenue generation, operating expenses, research and development investments, and any significant business developments that may have shaped the company's trajectory in the mid-1990s.

Key Highlights

1Amgen Inc. (AMGN) filed its quarterly report for the period ending June 29, 1994.
2The filing date was August 9, 1994, indicating timely reporting.
3This report provides a view into Amgen's financial and operational status during Q2 1994.
4The filing is part of Amgen's regular disclosure requirements to investors via the SEC.
5This document would contain crucial information for understanding the company's performance at that specific historical juncture.
6Investors should consult the full 10-Q for detailed financial statements and management discussion.
7The report is sourced from the SEC's EDGAR database, accessible to the public.

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 1994

Summary

Key Highlights

Frequently Asked Questions